A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: MEDIMMUNE LLC
- Phase: II
- Execution start: 09/06/2017
- End of execution: 31/12/2019
- PI: JOSE ANTONIO HURTADO SUAZO